Clinical Report: The Role of Bile Acids in Fontan Multisystem Dysfunction
Overview
This report addresses the correction of previously published figures regarding bile acids in Fontan patients. It emphasizes the importance of longitudinal clinics in managing multisystem dysfunction associated with the Fontan procedure.
Background
The Fontan procedure has significantly improved survival rates for patients with single ventricle congenital heart disease. However, these patients often face complex multisystem dysfunction, including Fontan-associated liver disease (FALD). Understanding the role of bile acids in this context is crucial for developing effective management strategies.
Data Highlights
No numerical data or trial results are presented in this correction article.
Key Findings
The original article has been corrected to accurately reflect the role of bile acids in Fontan patients.
Longitudinal clinics are essential for the comprehensive management of multisystem dysfunction in Fontan patients.
Elevated bile acids correlate with frailty and reduced exercise capacity in adults with Fontan circulation.
Structured multidisciplinary follow-up is recommended for Fontan patients to monitor liver health and other complications.
Emerging therapies targeting bile acid dysregulation may offer new treatment avenues for affected patients.
Clinical Implications
Healthcare providers should prioritize structured, multidisciplinary follow-up for Fontan patients to address the complexities of their care. Monitoring bile acid levels and liver function is essential for early detection and management of complications.
Conclusion
The correction of the figures in this article underscores the ongoing need for accurate information in managing the health of Fontan patients. Continued research into bile acids and their implications will enhance clinical outcomes.
